2,371 Natera, Inc. $NTRA Shares Purchased by Saxony Capital Management LLC

Saxony Capital Management LLC lifted its position in Natera, Inc. (NASDAQ:NTRA) by 256.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,297 shares of the medical research company’s stock after acquiring an additional 2,371 shares during the period. Saxony Capital Management LLC’s holdings in Natera were worth $1,363,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in Natera during the 2nd quarter worth about $2,962,770,000. Castle Hook Partners LP grew its stake in Natera by 24.1% during the 4th quarter. Castle Hook Partners LP now owns 2,167,869 shares of the medical research company’s stock valued at $496,637,000 after purchasing an additional 420,621 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its stake in Natera by 1.0% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,191,732 shares of the medical research company’s stock valued at $238,334,000 after purchasing an additional 11,793 shares during the last quarter. Maverick Capital Ltd. raised its stake in shares of Natera by 24.1% in the first quarter. Maverick Capital Ltd. now owns 1,171,633 shares of the medical research company’s stock worth $234,315,000 after purchasing an additional 227,605 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Natera by 10.7% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 833,376 shares of the medical research company’s stock worth $226,220,000 after purchasing an additional 80,440 shares during the period. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Natera Price Performance

Shares of NASDAQ:NTRA opened at $404.79 on Friday. The business’s 50 day moving average price is $356.78 and its 200-day moving average price is $274.42. Natera, Inc. has a 1 year low of $178.01 and a 1 year high of $437.41. The firm has a market capitalization of $58.35 billion, a price-to-earnings ratio of -297.64 and a beta of 1.50.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.02. The company had revenue of $752.75 million during the quarter, compared to analyst estimates of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The firm’s revenue was up 37.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.74) EPS. On average, sell-side analysts expect that Natera, Inc. will post -1.02 earnings per share for the current year.

Insider Activity at Natera

In other news, insider Solomon Moshkevich sold 15,160 shares of the business’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $326.89, for a total transaction of $4,955,652.40. Following the completion of the sale, the insider owned 110,859 shares of the company’s stock, valued at $36,238,698.51. The trade was a 12.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider John Fesko sold 6,517 shares of the business’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $321.53, for a total transaction of $2,095,411.01. Following the sale, the insider directly owned 197,257 shares of the company’s stock, valued at $63,424,043.21. This represents a 3.20% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 52,985 shares of company stock valued at $16,119,137. 5.05% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on NTRA shares. UBS Group lifted their target price on Natera from $290.00 to $435.00 and gave the stock a “buy” rating in a report on Wednesday, September 9th. Guggenheim raised their price objective on shares of Natera from $360.00 to $475.00 and gave the stock a “buy” rating in a research note on Thursday, October 1st. Stephens raised their target price on Natera from $305.00 to $350.00 and gave the company an “overweight” rating in a research report on Wednesday, August 12th. Piper Sandler lifted their price target on Natera from $249.00 to $363.50 and gave the company an “overweight” rating in a research note on Wednesday, August 12th. Finally, Leerink Partners set a $330.00 price target on Natera in a report on Friday, August 7th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $368.69.

Natera Profile

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to assess genetic and disease-related risks. The company uses technologies including cell-free DNA analysis and next-generation sequencing to support clinical decision-making in reproductive health, oncology and organ transplantation.

Its reproductive health offerings include Panorama, a noninvasive prenatal test that screens for certain chromosomal conditions, and Horizon, a carrier screening test that evaluates whether prospective parents carry genetic variants associated with inherited disorders.